AAP
AMRX icon

Arax Advisory Partners’s Amneal Pharmaceuticals AMRX Stock Holding History

Arax Advisory Partners’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$353K Buy
20,409
+18,745
+1,127% +$257K ﹤0.01% 1871
2026
Q1 		$21.1K Buy
1,664
+1,144
+220% +$15.4K ﹤0.01% 2084
2025
Q4 		$6.55K Sell
520
-20,965
-98% -$240K ﹤0.01% 2704
2025
Q3 		$215K Buy
21,485
+20,973
+4,096% +$188K ﹤0.01% 1233
2025
Q2 		$4.14K Buy
+512
New +$3.86K ﹤0.01% 2322

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Arax Advisory Partners's AMRX Position: Q2 2026 in Review

Arax Advisory Partners increased its Amneal Pharmaceuticals (AMRX) stake by 1,127% in Q2 2026, buying an estimated $257K and bringing the position to 20,409 shares worth $353K. The position accounts for ﹤0.01% of the portfolio, ranked #1871.

Arax Advisory Partners first reported a position in AMRX in Q2 2025 and has held it in 5 quarters since. 306 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Arax Advisory Partners held 20,409 shares of Amneal Pharmaceuticals worth $353K as of Q2 2026.
  • Arax Advisory Partners bought 18,745 Amneal Pharmaceuticals shares in Q2 2026, an estimated $257K.
  • Amneal Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #1871 holding.
  • Arax Advisory Partners first reported a position in Amneal Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 306 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.